Products
Platform
Research
Market
Learn
Compare Bajaj Finserv Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.38 | 1.87 |
NAV | ₹9.87 | ₹40.45 |
Fund Started | 06 Dec 2024 | 25 Jun 2018 |
Fund Size | ₹322.41 Cr | ₹6226.82 Cr |
Exit Load | 1% for redemption within 3 Months | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.38
1.87
NAV
₹9.87
₹40.45
Fund Started
06 Dec 2024
25 Jun 2018
Fund Size
₹322.41 Cr
₹6226.82 Cr
Exit Load
1% for redemption within 3 Months
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | - | 4.06% |
3 Year | - | 27.90% |
5 Year | - | 20.00% |
1 Year
-
4.06%
3 Year
-
27.90%
5 Year
-
20.00%
Holding Analysis
Equity | 95.64% | 97.55% |
Cash | 2.35% | 2.45% |
Equity
95.64%
97.55%
Cash
2.35%
2.45%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Divi's Laboratories Ltd. | 7.86% |
Sun Pharmaceutical Industries Ltd. | 7.21% |
Apollo Hospitals Enterprise Ltd. | 6.29% |
Cipla Ltd. | 5.61% |
Fortis Healthcare Ltd. | 3.51% |
Emcure Pharmaceuticals Ltd. | 3.45% |
Biocon Ltd. | 3.45% |
Dr. Reddy's Laboratories Ltd. | 3.44% |
Dr. Lal Pathlabs Ltd. | 3.34% |
Neuland Laboratories Ltd. | 3.25% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.58% |
Dr. Reddy's Laboratories Ltd. | 9.10% |
Divi's Laboratories Ltd. | 8.75% |
Aurobindo Pharma Ltd. | 8.25% |
Cipla Ltd. | 6.92% |
Lupin Ltd. | 5.43% |
Alkem Laboratories Ltd. | 4.05% |
Biocon Ltd. | 3.11% |
Gland Pharma Ltd. | 2.97% |
Mankind Pharma Ltd. | 2.95% |
Fund Manager
Name | Sorbh Gupta | Dharmesh Kakkad |
Start Date | 28 Jul 2025 | 23 Feb 2021 |
Name
Sorbh Gupta
Dharmesh Kakkad
Start Date
28 Jul 2025
23 Feb 2021
About Fund
Description | The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 06 Dec 2024 | 25 Jun 2018 |
Description
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
06 Dec 2024
25 Jun 2018